Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia

Medical Oncology

Volumn 31, Issue 5, 2014, Pages 1-7

  Huang, Bin Tao ^a   Zhao, Wei Hong ^a   Zeng, Qing Chun ^b   Li, Bing Sheng ^c   Chen, Rui lin ^d  

^a AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Huizhou Medical Institute   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Attenuated chemotherapy; Elderly patients

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; AGRANULOCYTOSIS; ALLERGIC REACTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTINUOUS INFUSION; CONVALESCENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY FAILURE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT DURATION; VERY ELDERLY;

EID: 84957432446     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0962-z     Document Type: Article

References (22)

1. Buchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol. 2002;6:46–59.
2. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521–8.
3. Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;29:609–15.
4. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896–903.
5. Dombret H, Raffoux E, Gardin C. New insights in the management of elderly patients with acute myeloid leukemia. Curr Opin Oncol. 2009;21:589–93.
6. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000;14:480–7.
7. Estey EH. How I treat older patients with AML. Blood. 2004;96:1670–3.
8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–5.
9. Farag SS, Archer KJ, Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia group B 8461. Blood. 2006;108:63–73.
10. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcome and costs of acute myeloid leukemia in the elderly. Arch Intern Med. 2002;162:1597–603.
11. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548–53.
12. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129–35.
13. Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, et al. NCCN practice guidelines for acute myelogenous leukemia. Oncology. 2000;14:53–61.
14. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–303.
15. Lee JH, Choi SJ, Lee JH, Park JH, Kim H, Joo YD, et al. Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. Ann Hematol. 2006;85:357–65.
16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–9.
17. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329–37.
18. Huang BT, Zeng QC, Yu J, Xiao Z, Li BS, Zhang CL, et al. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol. 2012;138:125–32.
19. Huang BT, Wang Y, Du QF, Yang J, Yu J, Zeng QC, et al. Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China. Int J Hematol. 2011;93:474–81.
20. Huang BT, Zeng QC, Yu J, Liu XL, Xiao Z, Zhu HQ. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China. Med Oncol. 2012;29:251–9.
21. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;24(361):1235–48.
22. Roboz GJ, Wissa U, Ritchie EK, Gergis U, Mayer S, Scandura JM, et al. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res. 2012;36:407–12.